RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by Types G1, G2, G3, G4, and G9.
It is administered as a 3-dose series to infants between the ages of 6 to 32 weeks.
The first dose of RotaTeq should be administered between 6 and 12 weeks of age.
The vaccination series consists of 3 ready-to-use liquid doses of RotaTeq administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4- to 10-week intervals.
The third dose should not be given after 32 weeks of age.
Rotavirus infection can lead to rotavirus gastroenteritis (RGE), which can cause mild, moderate, or severe symptoms.
Rotavirus can cause high fever, multiple episodes of vomiting and diarrhea, and can quickly lead to dehydration (loss of body fluids).
Dehydration is one of the most serious complications associated with rotavirus infection. If your child has a severe case of rotavirus and becomes very dehydrated, it can be life-threatening.
RotaTeq was extensively tested and was approved by the Food and Drug Administration (FDA) in February 2006.